Skip to main content

Prophylactic and therapeutic vaccination with carrier‐bound Bet v 1 peptides lacking allergen‐specific T cell epitopes reduces Bet v 1‐specific T cell responses via blocking antibodies in a murine model for birch pollen allergy

Buy Article:

$43.00 plus tax (Refund Policy)

Vaccines consisting of allergen‐derived peptides lacking IgE reactivity and allergen‐specific T cell epitopes bound to allergen‐unrelated carrier molecules have been suggested as candidates for allergen‐specific immunotherapy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: allergens; allergy vaccination; peptides; specific immunotherapy

Document Type: Research Article

Publication date: 01 February 2014

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more